-
JC-1 Mitochondrial Membrane Potential Assay
2026-08-14
The JC-1 Mitochondrial Membrane Potential Assay Kit provides a ratiometric view of mitochondrial depolarization and apoptosis. This guide connects ΔΨm interpretation with the hypoxia-activated BNNC cancer-therapy strategy while emphasizing controls, orthogonal validation, and practical assay limitations.
-
Anti-M1R/B6R Antibodies for Orthopoxvirus Protection
2026-08-14
The reference study maps antibody responses to the MPXV immunogens M1R and B6R and uses those data to develop antibody cocktails and bispecific formats. Its strongest translational result is protection against vaccinia virus in mice by a VH-CH1 switch region-inserting bispecific design, while also defining important boundaries for applying binding assays to antiviral antibody development.
-
Cy7 NHS Ester: Practical Labeling Protocol
2026-08-13
Cy7 NHS ester (SKU A8109) is a water-soluble Sulfo-Cy7 NHS Ester for labeling accessible amino groups on proteins, peptides, and related biomolecules for near-infrared fluorescent imaging. It is best used in freshly prepared, light-protected conjugation workflows and should not be treated as a universal thiol-labeling reagent or stored as a solution long term.
-
Deferoxamine Mesylate as a ROS Assay Probe
2026-08-13
Deferoxamine mesylate is more than an iron-chelating agent: it can function as a mechanistic probe for separating iron-dependent oxidative stress from rapid, iron-independent ROS toxicity. This guide translates recent platinum-therapy findings into practical assay design, while defining the limits of HIF-1α stabilization, hypoxia modeling, and cancer research applications.
-
Cy3 Rabbit Anti-Goat IgG (H+L) Antibody Guide
2026-08-12
Cy3 Rabbit Anti-Goat IgG (H+L) Antibody enables fluorescence detection of goat IgG primary antibodies in ICC/IF, IHC, flow cytometry, and ELISA workflows. It should not be treated as a primary antibody or used with non-goat immunoglobulins without application-specific validation.
-
Ceramides Drive RGNNV Infection: Lipidomics Insights
2026-08-12
This study uses global lipidomics and functional perturbation experiments to identify ceramide accumulation as a pro-viral feature of red-spotted grouper nervous necrosis virus infection. The evidence connects viral capsid protein, three ceramide-producing routes, and autophagy, while defining a mechanistic framework for studying lipid metabolism in viral nervous necrosis.
-
Optimized hGBA1 mRNA for Gaucher Disease
2026-08-11
A 2026 study developed optimized human GBA1 mRNA constructs that substantially increased glucocerebrosidase expression, supported lysosomal correction in GBA1-deficient cells, and produced detectable enzyme activity in mouse liver and spleen after lipid nanoparticle delivery. The work provides an important preclinical framework for evaluating mRNA replacement of lysosomal enzymes, while leaving questions about durability, biodistribution, neurological benefit, and clinical translation.
-
AIBP–LRP2 Control of CXCR4+ Collateral Vessels
2026-08-11
Zhu et al. identify an AIBP–LRP2–HDL–miR-223 pathway that suppresses CXCR4+ stemlike capillary endothelial cells and limits collateral circulation after ischemia. The study combines patient and mouse profiling with genetic, pharmacological, and mechanistic experiments to propose a two-phase model in which capillary endothelial cells first expand and then acquire arterial characteristics.
-
α7nAChR, Pyroptosis, and HIV-1 BBB Breakdown
2026-08-10
This study identifies α7nAChR-dependent endothelial pyroptosis as a mechanistic link between HIV-1 gp120 exposure and blood–brain barrier disruption. By placing the ROS/NF-κB/NLRP3 pathway at the center of this process and showing inhibition by memantine and metformin, the work provides a preclinical rationale for protecting BBB function in HIV-associated neurocognitive disorder.
-
Z-VEID-FMK: A Practical Caspase-6 Inhibitor Workflow
2026-08-09
Z-VEID-FMK provides a cell-permeable, irreversible way to test whether caspase-6 drives apoptotic substrate cleavage, neuronal injury, or immune-cell signaling. Its use can also extend to host–virus experiments, where caspase-6-dependent processing of a viral protein may connect apoptosis biology with interferon suppression.
-
ZK53 Activates Human ClpP to Arrest Lung Cancer
2026-08-08
The Nature Communications study identified ZK53 as a selective activator of human mitochondrial ClpP and showed that ClpP hyperactivation disrupts respiratory-chain proteostasis, suppresses oxidative phosphorylation, and arrests lung squamous cell carcinoma growth. Structural, biochemical, cellular, and mouse-model data connect mitochondrial electron transport chain loss with an ATM-linked DNA damage response, providing a mechanistic framework for targeting HsClpP in cancer research.
-
In Vitro Drug Response: Beyond Relative Viability
2026-08-07
Hannah R. Schwartz’s dissertation shows that relative viability and fractional viability capture different dimensions of anticancer drug response and should not be treated as interchangeable. Its central practical contribution is a framework for interpreting growth inhibition, cell killing, and response timing as related but distinct variables in in vitro studies.
-
Cy3 NHS Ester (Non-Sulfonated): Technical Guide and QC Check
2026-08-07
Cy3 NHS ester (non-sulfonated) provides a robust, high-sensitivity option for conjugating orange-emitting fluorescence to proteins, peptides, and oligonucleotides via primary amine groups. It excels in workflows compatible with organic co-solvents but is not suitable for strictly aqueous or highly labile biomolecules. Researchers should use this dye when precise, quantitative labeling and compatibility with TRITC filter sets are required.
-
Optimizing mRNA Assay Performance with EZ Cap™ Firefly Lucif
2026-08-06
Explore how EZ Cap™ Firefly Luciferase mRNA with Cap 1 structure enables next-generation assay reliability, with a unique focus on balancing immunogenicity and protein expression. This article offers advanced insights beyond typical workflows for bioluminescent reporter applications.
-
Optimizing FGFR-Driven Malignancies Research with BGJ398
2026-08-06
BGJ398 (NVP-BGJ398) empowers precise and selective interrogation of FGFR1/2/3 signaling, enabling advanced workflows in oncology and developmental biology. This guide delivers actionable protocols, troubleshooting insights, and key innovations from recent comparative studies, helping researchers maximize their results when targeting FGFR-driven malignancies.